Oral Wegovy pill vs. injection: cost, effectiveness, switching

The pill is real now. The comparison isn’t simple.

On December 22, 2025, the FDA approved a 25 mg oral semaglutide tablet under the Wegovy name (NDA 218316) for chronic weight management and to reduce cardiovascular risk in adults with overweight or obesity and established heart disease, according to the FDA prescribing information. It’s the first oral GLP-1 approved for weight management.

A milestone, yes. A reason to treat pill and shot as interchangeable, no. No published randomized trial has put the 25 mg tablet head-to-head against the subcutaneous Wegovy injection in the same people, at the same time, with the same endpoints. Every effectiveness comparison you’ll read, including the ones below, is a cross-trial comparison. That doesn’t make the numbers useless. It makes them directional, not proof that one product beats the other.

For most people choosing between pill and shot, the decision hinges less on a percentage point here or there. It hinges on whether you’ll actually take the drug correctly every day, whether your gut tolerates it, and what it costs you out of pocket.

What the efficacy numbers actually show

Start with the tablet’s own pivotal trial. In OASIS 4, a phase 3 trial of 307 adults without diabetes (BMI ≥30, or ≥27 with a weight-related complication), 205 people took oral semaglutide 25 mg and 102 took placebo for 71 weeks. By week 64, the oral group had lost an estimated 13.6% of body weight on average, versus 2.2% on placebo. That’s a treatment difference of 11.4 percentage points (95% CI, −13.9 to −9.0; P<0.001). Thirty percent of the treatment group lost at least 20% of their body weight, versus 3% on placebo.

Novo Nordisk published its own figure in the company’s FDA approval announcement: 16.6% mean weight loss at 64 weeks among people who actually adhered to treatment, versus 2.7% on placebo. That’s not a contradiction of the 13.6% above. OASIS 4 reports an intention-to-treat estimate, which includes everyone who started the trial, dropouts included. Novo’s 16.6% counts adherers only. The two numbers answer different questions: what happens on average to everyone who starts, and what happens if you take the drug as directed.

Now the injection. In STEP 1, weekly subcutaneous semaglutide 2.4 mg produced 17.3% average weight loss at 68 weeks in adults without diabetes, a placebo-subtracted difference of roughly 12.4 percentage points. And in OASIS 1, the 50 mg oral dose (not the 25 mg dose that got the Wegovy approval) produced a 12.7 percentage-point difference over placebo, close to the injection’s 12.4.

Side by side, the numbers cluster in a similar range. But “similar in a cross-trial comparison” is not “equivalent.” The trials enrolled different people, ran for different lengths, and measured adherence differently. Until someone runs the head-to-head trial, treat any claim of definitive superiority, in either direction, with skepticism.

Why the pill has an unusual set of rules

The tablet’s biggest practical difference from the injection isn’t the efficacy data. It’s the biology of getting the drug into your bloodstream at all. Semaglutide is a large peptide, and on its own it’s poorly absorbed through the stomach lining. The tablet is co-formulated with an absorption enhancer called SNAC (salcaprozate sodium) to push a usable amount across the gastric epithelium. Even with that help, systemic bioavailability is only about 0.8-1% under recommended fasting conditions, versus roughly 89% for the injection, according to a pharmacology review in NCBI’s StatPearls.

Hence the strict dosing rules. The Rybelsus label, whose dosing mechanics the oral Wegovy tablet shares, requires taking the pill on an empty stomach with no more than 4 oz of plain water, at least 30 minutes before the day’s first food, drink, or other oral medication. Food and extra water dilute the absorption enhancer and sharply cut how much drug gets absorbed. Miss that window regularly and you may be under-dosing yourself without knowing it. A once-weekly injection doesn’t carry that burden.

Side effects: a real-world signal, not a controlled comparison

Both formulations cause GI side effects; that’s well established. Whether the pill causes more is less clear. A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS, Q1 2018 through Q2 2023, 19,289 semaglutide-related reports) found gastrointestinal disorders in 30.19% of oral semaglutide reports versus 27.76% of subcutaneous reports, and serious outcomes in 3.07% of oral reports versus 2.25% of subcutaneous reports.

The gap is modest, and it comes from spontaneous adverse-event reporting rather than a controlled trial. FAERS data is subject to reporting bias: people report side effects more often for newer or more talked-about drugs, and the database can’t establish true incidence or prove the drug caused the event. Read it as hypothesis-generating, not as evidence that the pill is meaningfully harder on the gut than the shot.

Separately, the Rybelsus label warns that the drug is not recommended in patients with severe gastroparesis, and it carries a warning about serious hypersensitivity reactions including anaphylaxis and angioedema, according to the FDA prescribing information. If you have a history of severe gastroparesis, flag it specifically when discussing a switch with a prescriber. If you had GI or other side effects on the injection and are weighing a switch, raise that too.

One more data point worth keeping in view, though it comes from a diabetes population rather than the obesity-only group the pill is approved for: PIONEER PLUS randomized 1,606 people with type 2 diabetes across oral semaglutide 14 mg, 25 mg, and 50 mg for 68 weeks. The 25 mg and 50 mg doses cut HbA1c by 1.9 and 2.2 percentage points respectively from a 9.0% baseline, versus 1.5 points with 14 mg, a statistically significant dose-response. The trial says nothing about weight loss in people without diabetes. What it does show is that higher oral doses produce a stronger effect, in a dose-dependent way, which is a useful pattern for understanding how the drug behaves.

What it actually costs

List price for the oral Wegovy tablet matches the injection pen: $1,349 per month, per Novo Nordisk. Through Novo’s direct-to-consumer cash-pay channels, starter doses (1.5 mg and 4 mg) begin at $149 a month and rise to $199, and the two highest doses (9 mg and 25 mg) run $299 a month.

Medicare access is changing, but narrowly and temporarily. Starting July 1, 2026, the CMS Medicare GLP-1 Bridge demonstration lets eligible Part D beneficiaries get Wegovy (either form) or Zepbound for a $50 copay per 30-day supply, through December 31, 2027. Not everyone qualifies. You’re excluded if you already have GLP-1 coverage through your Part D plan, or if your qualifying condition is type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. This is a two-and-a-half-year demonstration program, not permanent coverage. The federal statutory exclusion on Medicare covering weight-loss drugs is still in place, and per HHS’s own policy analysis, making it permanent would require an act of Congress.

If both branded options are priced out of reach, it’s worth understanding how compounded semaglutide compares on cost and the current rules for compounding, since that market has shifted substantially in 2026.

Frequently Asked Questions

Is the new oral Wegovy pill as effective as the Wegovy injection for weight loss? No randomized head-to-head trial exists, so nobody can say for certain. Cross-trial numbers land in a similar range: OASIS 4’s oral 25 mg showed -13.6% vs. -2.2% for placebo (intention-to-treat), Novo’s adherent-population figure was 16.6% vs. 2.7%, and STEP 1’s injectable 2.4 mg showed 17.3% total weight loss. Similar range, different trials, different populations. That is not proven equivalence.

Why does the oral pill need to be taken on an empty stomach with only a small sip of water? The tablet relies on the absorption enhancer SNAC to get semaglutide across the stomach lining, and even then only about 0.8-1% of the dose reaches the bloodstream. Food or more than 4 oz of water dilutes the enhancer and can sharply cut absorption, per the FDA label.

Does the oral pill cause more nausea and GI side effects than the injection? The evidence is modest, not definitive. A FAERS-based analysis of real-world adverse-event reports found GI disorders in 30.19% of oral semaglutide reports versus 27.76% of subcutaneous reports. That’s spontaneous reporting data, not a controlled trial, so it can’t establish true incidence or prove causation.

How much does the oral Wegovy pill cost compared to the injection? Same list price: $1,349 a month for either form. Through Novo’s cash-pay program, starter doses run $149-$199 a month, and the top doses (including the 25 mg tablet) run $299 a month. Check current GLP-1 coupons and discount programs before paying list price.

Will Medicare cover the oral Wegovy pill in 2026? Only through the CMS GLP-1 Bridge demonstration starting July 1, 2026, which caps copays at $50 a month through the end of 2027 for eligible beneficiaries. It excludes people who already have Part D GLP-1 coverage or whose qualifying condition is diabetes, sleep apnea, or fatty liver disease. Broader, permanent Medicare coverage would need Congress to act.

Who is a good candidate to switch from injectable Wegovy to the oral pill? That’s a conversation for your prescriber, not a rule this data supports on its own. Relevant factors include needle aversion, whether you can reliably fast for 30 minutes before the pill and limit water intake, and whether you have a history of severe gastroparesis, which the label advises against. Cost and insurance fit matter too. None of the sources here support a blanket recommendation either way.

This article is for informational purposes only and is not medical advice. Talk to your healthcare provider before starting, stopping, or changing any medication.